Human antibody response during sepsis against targets expressed by methicillin resistant Staphylococcus aureus

Citation
U. Lorenz et al., Human antibody response during sepsis against targets expressed by methicillin resistant Staphylococcus aureus, FEMS IM MED, 29(2), 2000, pp. 145-153
Citations number
45
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Immunology
Journal title
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
ISSN journal
0928-8244 → ACNP
Volume
29
Issue
2
Year of publication
2000
Pages
145 - 153
Database
ISI
SICI code
0928-8244(200010)29:2<145:HARDSA>2.0.ZU;2-K
Abstract
The identification of target structures is a prerequisite for the developme nt of new treatment options, like antibody based therapy, against methicill in resistant Staphylococcus aureus (MRSA). In this study we identified immu nodominant structures which were expressed in vivo during sepsis caused by MRSA. Using human sera we compared the immune response of humans with MRSA sepsis with the immune response of normal individuals and asymptomatically colonized individuals. We identified and characterized four staphylococcal specific antigenic structures. One target is a staphylococcal protein of 29 kDa that exhibited 29% identity to secreted protein SceA precursor of Stap hylococcus carnosus. The putative function of this protein, which was desig nated IsaA (immunodominant staphylococcal antigen), is unknown. The second target is an immunodominant protein of 17 kDa that showed no homology to an y currently known protein. This immunodominant protein was designated IsaB. The third and fourth antigens are both immunodominant proteins of 10 kDa. One of these proteins showed 100% identity to major cold shock protein CspA of S. aureus and the other protein was identified as the phosphocarrier pr otein Hpr of S. aureus. The identified immunodominant proteins may serve as potential targets for the development of antibody based therapy against MR SA. (C) 2000 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.